{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "INR", "marketState": "CLOSED", "exchangeTimezoneShortName": "IST", "gmtOffSetMilliseconds": 19800000, "esgPopulated": false, "regularMarketChangePercent": -0.38294613, "regularMarketPrice": 195.1, "exchange": "NSI", "shortName": "SUN PHARMA ADV", "longName": "Sun Pharma Advanced Research Company Limited", "messageBoardId": "finmb_29870145", "exchangeTimezoneName": "Asia/Kolkata", "market": "in_market", "regularMarketTime": 1683885595, "regularMarketDayHigh": 197.1, "regularMarketDayRange": "194.2 - 197.1", "regularMarketDayLow": 194.2, "regularMarketVolume": 202693, "regularMarketPreviousClose": 195.85, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "NSE", "financialCurrency": "INR", "regularMarketOpen": 195.95, "averageDailyVolume3Month": 1109610, "averageDailyVolume10Day": 288461, "fiftyTwoWeekLowChange": 33.0, "fiftyTwoWeekLowChangePercent": 0.20357803, "fiftyTwoWeekRange": "162.1 - 265.85", "fiftyTwoWeekHighChange": -70.75, "fiftyTwoWeekHighChangePercent": -0.2661275, "fiftyTwoWeekLow": 162.1, "fiftyTwoWeekHigh": 265.85, "earningsTimestamp": 1676285940, "earningsTimestampStart": 1684148340, "earningsTimestampEnd": 1684497600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -7.83, "epsForward": 43.3, "sharesOutstanding": 324521984, "bookValue": -4.372, "fiftyDayAverage": 185.771, "fiftyDayAverageChange": 9.32901, "fiftyDayAverageChangePercent": 0.050217796, "twoHundredDayAverage": 212.83925, "twoHundredDayAverageChange": -17.739243, "twoHundredDayAverageChangePercent": -0.08334573, "marketCap": 63870865408, "forwardPE": 4.505774, "priceToBook": -44.624886, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1042515900000, "priceHint": 2, "regularMarketChange": -0.75, "symbol": "SPARC.NS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "17-B, Mahal Industrial Estate", "address2": "Off Mahakali Caves Road Andheri (East)", "city": "Mumbai", "zip": "400093", "country": "India", "phone": "91 22 6645 5645", "fax": "91 22 6645 5685", "website": "https://www.sparc.life", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.", "fullTimeEmployees": 403, "companyOfficers": [{"maxAge": 1, "name": "Mr. Anilkumar  Raghavan", "age": 53, "title": "Chief Exec. Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chetan M. Rajpara", "title": "Chief Financial Officer", "fiscalYear": 2020, "totalPay": {"raw": 15143000, "fmt": "15.14M", "longFmt": "15,143,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Siu-Long  Yao", "title": "Exec. VP Clinical Devel. & Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jaydeep  Issrani", "title": "Sr. Gen. Mang. of Bus. Devel., Corp. Communication & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dinesh Poosraj Lahoti", "title": "Company Sec. & Compliance Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rajesh  Ranganathan", "title": "Vice-Pres Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Shanta  Gupta", "title": "Chief Human Resource Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nitin K. Damle Ph.D.", "title": "Sr. VP & Chief Innovation Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Vikram  Ramanathan", "title": "VP & Head of Translational Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Venkata  Palle", "title": "Exec. VP & Global Head of Drug Discovery and Preclinical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1609372800, "maxAge": 86400}}], "error": null}}